Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
May 09, 2018 07:30 ET | Adaptimmune Therapeutics plc
- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO -  - Guidance confirmed, funded...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
April 25, 2018 08:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, U.K., April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Changes to Board of Directors
April 12, 2018 08:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, U.K., April 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that, in a planned...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
April 06, 2018 08:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, U.K., April 06, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells
March 15, 2018 07:30 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, U.K., March 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported three partial responses (two...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
March 15, 2018 07:30 ET | Adaptimmune Therapeutics plc
- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors - - Clinical momentum continues: dosing...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018
March 05, 2018 12:12 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, March 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
January 08, 2018 08:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company
January 08, 2018 08:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
Adaptimmune logo Colour_white background_no strap.jpg
Paul Stead Joins Adaptimmune as Vice President of Business Development
January 04, 2018 08:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, England, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B....